Literature DB >> 25558836

Benign prostatic hyperplasia in 2014: Innovations in medical and surgical treatment.

Cosimo De Nunzio1, Andrea Tubaro1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25558836     DOI: 10.1038/nrurol.2014.360

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  9 in total

1.  Multicentre prospective crossover study of the 'prostatic urethral lift' for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Anthony L Cantwell; William K Bogache; Steven F Richardson; Ronald F Tutrone; Jack Barkin; James E Fagelson; Peter T Chin; Henry H Woo
Journal:  BJU Int       Date:  2014-04       Impact factor: 5.588

2.  Update on AUA guideline on the management of benign prostatic hyperplasia.

Authors:  Kevin T McVary; Claus G Roehrborn; Andrew L Avins; Michael J Barry; Reginald C Bruskewitz; Robert F Donnell; Harris E Foster; Chris M Gonzalez; Steven A Kaplan; David F Penson; James C Ulchaker; John T Wei
Journal:  J Urol       Date:  2011-03-21       Impact factor: 7.450

3.  The evolving picture of lower urinary tract symptom management.

Authors:  Andrea Tubaro; Cosimo De Nunzio; Federica Puccini; Fabrizio Presicce
Journal:  Eur Urol       Date:  2014-10-29       Impact factor: 20.096

4.  Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study.

Authors:  Matthias Oelke; François Giuliano; Simin K Baygani; Thomas Melby; Angelina Sontag
Journal:  BJU Int       Date:  2014-10       Impact factor: 5.588

5.  High prevalence of benign prostatic hypertrophy in the community.

Authors:  W M Garraway; G N Collins; R J Lee
Journal:  Lancet       Date:  1991-08-24       Impact factor: 79.321

6.  Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.

Authors:  Luca Cindolo; Luisella Pirozzi; Caterina Fanizza; Marilena Romero; Andrea Tubaro; Riccardo Autorino; Cosimo De Nunzio; Luigi Schips
Journal:  Eur Urol       Date:  2014-11-20       Impact factor: 20.096

Review 7.  Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?

Authors:  João Silva; Carlos Martins Silva; Francisco Cruz
Journal:  Curr Opin Urol       Date:  2014-01       Impact factor: 2.309

8.  A European multicenter randomized noninferiority trial comparing 180 W GreenLight XPS laser vaporization and transurethral resection of the prostate for the treatment of benign prostatic obstruction: 12-month results of the GOLIATH study.

Authors:  Alexander Bachmann; Andrea Tubaro; Neil Barber; Frank d'Ancona; Gordon Muir; Ulrich Witzsch; Marc-Oliver Grimm; Joan Benejam; Jens-Uwe Stolzenburg; Antony Riddick; Sascha Pahernik; Herman Roelink; Filip Ameye; Christian Saussine; Franck Bruyère; Wolfgang Loidl; Tim Larner; Nirjan-Kumar Gogoi; Richard Hindley; Rolf Muschter; Andrew Thorpe; Nitin Shrotri; Stuart Graham; Moritz Hamann; Kurt Miller; Martin Schostak; Carlos Capitán; Helmut Knispel; J Andrew Thomas
Journal:  J Urol       Date:  2014-09-16       Impact factor: 7.450

9.  Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.

Authors:  Marcus J Drake; Christopher Chapple; Roman Sokol; Matthias Oelke; Klaudia Traudtner; Monique Klaver; Ted Drogendijk; Philip Van Kerrebroeck
Journal:  Eur Urol       Date:  2014-07-25       Impact factor: 20.096

  9 in total
  1 in total

1.  Potential Therapeutic Effects of Underground Parts of Kalanchoe gastonis-bonnieri on Benign Prostatic Hyperplasia.

Authors:  Antonio Palumbo; Livia Marques Casanova; Maria Fernanda Paresqui Corrêa; Nathalia Meireles Da Costa; Luiz Eurico Nasciutti; Sônia Soares Costa
Journal:  Evid Based Complement Alternat Med       Date:  2019-01-02       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.